Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00359112 | AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes | PHASE3 | COMPLETED | 544 | — | — | Feb 1, 2004 | - | May 18, 2009 | 142 | Belgium, France +9 |
| Name | Type | Description |
|---|---|---|
| metformin | DRUG | - |
| sulphonylurea | DRUG | - |
| Avandamet | DRUG | - |
Inclusion criteria: * Body mass index \> or = to 25 kg/m2. * HbA1c \> or =7% and \< or =10% at screening. * FPG \> or = 7.0mmol/L (126mg/dL) at visit 2. * Receiving at least 0.85g of metformin at constant dose(s) for at least 8 weeks prior to visit 1a. * Female subjects must be postmenopausal or us...